Dopaminski receptor D4 (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dopaminski receptor D4" in Serbian language version.

refsWebsite

Global rank Serbian rank

16nih.gov

4^th place

8^th place

13doi.org

2^nd place

4^th place

3aspetjournals.org

6,663^rd place

3,586^th place

1archive.org

6^th place

5^th place

1web.archive.org

1^st place

archive.org

Moreland RB, Patel M, Hsieh GC, Wetter JM, Marsh K, Brioni JD (2005). „A-412997 is a selective dopamine D₄ receptor agonist in rats”. Pharmacol. Biochem. Behav. 82 (1): 140—7. PMID 16153699. doi:10.1016/j.pbb.2005.08.001.

aspetjournals.org

jpet.aspetjournals.org

Patel S; Freedman S; Chapman KL (1. 11. 1997). „Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor”. J. Pharmacol. Exp. Ther. 283 (2): 636—47. PMID 9353380.
Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL (1. 10. 1998). „ S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride”. J. Pharmacol. Exp. Ther. 287 (1): 167—86. PMID 9765336. Архивирано из оригинала 12. 07. 2003. г. Приступљено 09. 04. 2012.

molpharm.aspetjournals.org

Patel S; Patel S; Marwood R (1996). „Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor”. Mol. Pharmacol. 50 (6): 1658—64. PMID 8967990. ^{[мртва веза]}

doi.org

Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991). „Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine”. Nature. 350 (6319): 610—4. PMID 1840645. doi:10.1038/350610a0.
Neve KA, Seamans JK, Trantham-Davidson H (2004). „Dopamine receptor signaling”. J. Recept. Signal Transduct. Res. 24 (3): 165—205. PMID 15521361. doi:10.1081/RRS-200029981.
Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE (2006). „WAY-100635 is a potent dopamine D4 receptor agonist”. Psychopharmacology (Berl.). 188 (2): 244—51. PMID 16915381. doi:10.1007/s00213-006-0490-4.
Moreland RB, Patel M, Hsieh GC, Wetter JM, Marsh K, Brioni JD (2005). „A-412997 is a selective dopamine D₄ receptor agonist in rats”. Pharmacol. Biochem. Behav. 82 (1): 140—7. PMID 16153699. doi:10.1016/j.pbb.2005.08.001.
Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, Patel M, Kolasa T, Nakane M, Uchic ME, Miller LN, Terranova MA, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino BR, Lynch JJ, Sullivan JP, Hsieh GC, Moreland RB, Brioni JD, Stewart AO (2004). „Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction”. Journal of Medicinal Chemistry. 47 (15): 3853—64. PMID 15239663. doi:10.1021/jm030505a.
Patel MV; Kolasa T; Mortell K (2006). „Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction”. J. Med. Chem. 49 (25): 7450—65. PMID 17149874. doi:10.1021/jm060662k.
Hübner H, Kraxner J, Gmeiner P (2000). „Cyanoindole derivatives as highly selective dopamine D₄ receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments”. J. Med. Chem. 43 (23): 4563—9. PMID 11087581. doi:10.1021/jm0009989.
Kolasa T; Matulenko MA; Hakeem AA (2006). „1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction”. J. Med. Chem. 49 (17): 5093—109. PMID 16913699. doi:10.1021/jm060279f.
Enguehard-Gueiffier C; Hübner H; El Hakmaoui A (2006). „2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist”. J. Med. Chem. 49 (13): 3938—47. PMID 16789750. doi:10.1021/jm060166w.
Nakane M; Cowart MD; Hsieh GC (2005). „2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist”. Neuropharmacology. 49 (1): 112—21. PMID 15992586. doi:10.1016/j.neuropharm.2005.02.004.
Prante O, Tietze R, Hocke C, Löber S, Hübner H, Kuwert T, Gmeiner P (2008). „Synthesis, Radiofluorination, and In Vitro Evaluation of Pyrazolo[1,5-a]pyridine-Based Dopamine D₄ Receptor Ligands: Discovery of an Inverse Agonist Radioligand for PET”. J. Med. Chem. 51 (6): 1800—10. PMID 18307287. doi:10.1021/jm701375u.
Kulagowski JJ; Broughton HB; Curtis NR (1996). „3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor”. J. Med. Chem. 39 (10): 1941—2. PMID 8642550. doi:10.1021/jm9600712.
Lanig H, Utz W, Gmeiner P (2001). „Comparative molecular field analysis of dopamine D₄ receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine”. J. Med. Chem. 44 (8): 1151—7. PMID 11312915. doi:10.1021/jm001055e.

nih.gov

ncbi.nlm.nih.gov

Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991). „Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine”. Nature. 350 (6319): 610—4. PMID 1840645. doi:10.1038/350610a0.
Neve KA, Seamans JK, Trantham-Davidson H (2004). „Dopamine receptor signaling”. J. Recept. Signal Transduct. Res. 24 (3): 165—205. PMID 15521361. doi:10.1081/RRS-200029981.
Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE (2006). „WAY-100635 is a potent dopamine D4 receptor agonist”. Psychopharmacology (Berl.). 188 (2): 244—51. PMID 16915381. doi:10.1007/s00213-006-0490-4.
Moreland RB, Patel M, Hsieh GC, Wetter JM, Marsh K, Brioni JD (2005). „A-412997 is a selective dopamine D₄ receptor agonist in rats”. Pharmacol. Biochem. Behav. 82 (1): 140—7. PMID 16153699. doi:10.1016/j.pbb.2005.08.001.
Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, Patel M, Kolasa T, Nakane M, Uchic ME, Miller LN, Terranova MA, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino BR, Lynch JJ, Sullivan JP, Hsieh GC, Moreland RB, Brioni JD, Stewart AO (2004). „Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction”. Journal of Medicinal Chemistry. 47 (15): 3853—64. PMID 15239663. doi:10.1021/jm030505a.
Patel MV; Kolasa T; Mortell K (2006). „Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction”. J. Med. Chem. 49 (25): 7450—65. PMID 17149874. doi:10.1021/jm060662k.
Hübner H, Kraxner J, Gmeiner P (2000). „Cyanoindole derivatives as highly selective dopamine D₄ receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments”. J. Med. Chem. 43 (23): 4563—9. PMID 11087581. doi:10.1021/jm0009989.
Kolasa T; Matulenko MA; Hakeem AA (2006). „1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction”. J. Med. Chem. 49 (17): 5093—109. PMID 16913699. doi:10.1021/jm060279f.
Enguehard-Gueiffier C; Hübner H; El Hakmaoui A (2006). „2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist”. J. Med. Chem. 49 (13): 3938—47. PMID 16789750. doi:10.1021/jm060166w.
Nakane M; Cowart MD; Hsieh GC (2005). „2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist”. Neuropharmacology. 49 (1): 112—21. PMID 15992586. doi:10.1016/j.neuropharm.2005.02.004.
Prante O, Tietze R, Hocke C, Löber S, Hübner H, Kuwert T, Gmeiner P (2008). „Synthesis, Radiofluorination, and In Vitro Evaluation of Pyrazolo[1,5-a]pyridine-Based Dopamine D₄ Receptor Ligands: Discovery of an Inverse Agonist Radioligand for PET”. J. Med. Chem. 51 (6): 1800—10. PMID 18307287. doi:10.1021/jm701375u.
Kulagowski JJ; Broughton HB; Curtis NR (1996). „3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor”. J. Med. Chem. 39 (10): 1941—2. PMID 8642550. doi:10.1021/jm9600712.
Patel S; Freedman S; Chapman KL (1. 11. 1997). „Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor”. J. Pharmacol. Exp. Ther. 283 (2): 636—47. PMID 9353380.
Patel S; Patel S; Marwood R (1996). „Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor”. Mol. Pharmacol. 50 (6): 1658—64. PMID 8967990. ^{[мртва веза]}
Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL (1. 10. 1998). „ S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride”. J. Pharmacol. Exp. Ther. 287 (1): 167—86. PMID 9765336. Архивирано из оригинала 12. 07. 2003. г. Приступљено 09. 04. 2012.
Lanig H, Utz W, Gmeiner P (2001). „Comparative molecular field analysis of dopamine D₄ receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine”. J. Med. Chem. 44 (8): 1151—7. PMID 11312915. doi:10.1021/jm001055e.

web.archive.org

Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL (1. 10. 1998). „ S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride”. J. Pharmacol. Exp. Ther. 287 (1): 167—86. PMID 9765336. Архивирано из оригинала 12. 07. 2003. г. Приступљено 09. 04. 2012.